In the SURMOUNT-1 trial, participants on the highest dose of tirzepatide lost an average of 22.5 percent of their body weight at 72 weeks (Jastreboff et al., NEJM , 2022), compared to roughly 15 percent with semaglutide 2.4 mg in the STEP 1 trial (Wilding et al., NEJM , 2021)
Mazini L, Rochette L, Admou B, Amal S, Malka G
Every year, the World Anti-Doping Agency (WADA) publishes an updated Prohibited List
[1] It typically occurs in the skin, but may rarely occur in the mouth, intestines, or eye (uveal melanoma)
Front Endocrinol 14:1240263 Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP (2023) Artificial intelligence in pharmaceutical technology and drug delivery design